Portfolio Companies News
October 22, 2020GenSight Biologics S A : successful...
Paris, France, October 22 2020, 6.30 am CEST The following information is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or ... read more
October 21, 2020InCarda Therapeutics Raises $30 Mil...
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for Presentation at American Heart Association Scientific Sessions 2020; Pivotal Phase 3 Study Planned f... read more
October 19, 2020Updated CERAMENT BONE VOID FILLER (...
Lund, Sweden, 15:00 CET, 19 October 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces that the company, through a 510 (k) to the Food and Drug Administration (FDA), has updated its CERAMENT® BONE VOID FILLER (BVF) instructions for use fo... read more
October 19, 2020Oncopeptides has submitted an Inves...
STOCKHOLM — October 19, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 – a second drug candidate based on the proprietary Peptide ... read more
October 15, 2020GenSight Biologics Reports Cash Pos...
Paris, France, October 15, 2020, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today re... read more
August 05, 2020Q2 2020 General Market Overview
Since the start in 1996, HealthCap funds have invested in 116 portfolio companies.
46 of the portfolio companies have been taken public on nine different markets.
26 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.